Loading clinical trials...
Loading clinical trials...
A Randomized Phase II Study to Assess the Activity of TroVax® (MVA-5T4) Plus Docetaxel Versus Docetaxel Alone in Subjects With Progressive Hormone Refractory Prostate Cancer
Conditions
Interventions
Docetaxel
TroVax
Locations
7
United States
San Bernardino Urology
San Bernardino, California, United States
Stanford University Medical Center
Stanford, California, United States
Rush University Medical Center
Chicago, Illinois, United States
GU Research Network
Omaha, Nebraska, United States
New York University Cancer Institute
New York, New York, United States
Gabrail Cancer Center Research
Canton, Ohio, United States
Start Date
August 1, 2010
Primary Completion Date
March 1, 2013
Completion Date
March 1, 2013
Last Updated
October 19, 2020
NCT02955082
NCT00667199
NCT01741116
NCT00411528
NCT02691975
NCT00286091
Lead Sponsor
Oxford BioMedica
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions